Apimeds Pharmaceuticals US (APUS) Profit After Tax (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Profit After Tax of -$1.2 million for Q4 2025, down 270.72% on a YoY basis from $676709.6 in Q4 2024, and up 35.14% quarter-over-quarter from -$1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Profit After Tax (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Profit After Tax for 2 years, with the latest figure at -$1.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 270.72% year-over-year to -$1.2 million; the trailing twelve-month figure through Dec 2025 stood at -$6.0 million (down 331.74% YoY), and the FY2025 full-year result was -$6.0 million, down 331.74% from the prior year.
  • Profit After Tax for Q4 2025 stood at -$1.2 million, up from -$1.8 million in the prior quarter.
  • The five-year high for Profit After Tax was -$296473.0 in Q1 2024, with the low at -$2.7 million in Q2 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Teva Pharmaceutical Industries 39.97 Bn 36.23 Bn 1.97 Bn 369.00 Mn
2 Zoetis 33.59 Bn 31.65 Bn 1.62 Bn 601.00 Mn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn 274.90 Mn
4 Neurocrine Biosciences 16.10 Bn 14.78 Bn 800.70 Mn 197.90 Mn
5 Aurora Cannabis 15.56 Bn 15.47 Bn 21.72 Mn 11.81 Mn
6 Elanco Animal Health 12.04 Bn 11.61 Bn 785.00 Mn 57.00 Mn
7 Alkermes 7.36 Bn 6.84 Bn -116.06 Mn 16.20 Mn
8 Lantheus Holdings 6.74 Bn 6.24 Bn 230.92 Mn 118.42 Mn
9 Liquidia 6.27 Bn 6.04 Bn 121.79 Mn 52.86 Mn
10 Apimeds Pharmaceuticals US 14.04 Mn 10.40 Mn - -1.16 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -1.16 Mn
Sep 30, 2025 -1.78 Mn
Jun 30, 2025 -2.66 Mn
Mar 31, 2025 -402,397.00
Dec 31, 2024 -311,633.00
Sep 30, 2024 -332,521.00
Jun 30, 2024 -449,363.00
Mar 31, 2024 -296,473.00